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A B S T R A C T
Background: Endothelial dysfunction causes vasomotor dysregulation and vascular stiffening in addition
to structural changes. By inﬂuencing NO synthesis, deﬁciency of L-arginine relative to asymmetric
dimethylarginine (ADMA), which is an L-arginine derivative that acts as a competitive NO synthase
inhibitor, may lead to the promotion of arterial stiffness. This study investigated the relationship
between the L-arginine/ADMA ratio and brachial-ankle pulse wave velocity (baPWV), an indicator of
arterial stiffness.
Methods and results: This cross-sectional study enrolled 74 patients (62 men, 12 women; mean age,
67  10 years) undergoing elective coronary angiography. A total of 54 (73%) patients had coronary artery
disease. Serum L-arginine and ADMA were measured by high-performance liquid chromatography with
ﬂuorescence detection. The ratio of L-arginine to ADMA and the serum L-arginine level was associated with
baPWV in univariate regression analysis (L-arginine/ADMA ratio: b = 0.323, p = 0.005; L-arginine:
b = 0.247, p = 0.034). In addition, baPWV was related to blood hemoglobin concentration, hematocrit,
brain natriuretic peptide level, symmetric dimethylarginine, renal function, blood pressure, and heart rate. In
multivariate analysis, the L-arginine/ADMA ratio was a signiﬁcant predictor of baPWV (b = 0.310,
p < 0.001). In subgroup analyses, the L-arginine/ADMA ratio was associated with baPWV in elderly patients
(n = 46, b = 0.359, p = 0.004), and in younger patients (n = 28, b = 0.412, p = 0.006).
Conclusion: A low L-arginine/ADMA ratio may be associated with high baPWV in patients undergoing
coronary angiography.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Arterial stiffness develops with aging, in part as a consequence
of lifestyle-related diseases including hypertension, diabetes
mellitus, renal dysfunction, and physical dysfunction, and the
progression is associated with further cardiovascular events [1–3].
The primary cause of arterial stiffness is alteration of medial
structural components by hemodynamic stress. Matrix metallo-
proteinases are involved in overproduction of abnormal collagen
and degradation of elastin in the extracellular matrix [4].
Furthermore, the accumulation of glycation end products and* Corresponding author at: Department of Cardiovascular Medicine, National
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightscalcium deposition contribute to the loss of vascular integrity and
elasticity. Neurohormonal factors such as angiotensin II, insulin,
and sympathetic nerve activation also have a role in the
progression of vessel wall stiffness.
Endothelial dysfunction may promote vascular stiffening in
addition to the structural changes [5,6], because it causes
inappropriate vasoconstriction in peripheral arterioles leading to
intima–media thickening [7]. Elevated peripheral arterial resis-
tance promotes pulse wave reﬂection in the central arteries, and
causes additional stress on the vessel wall. To maintain endothelial
function in the large conductive arteries, nitric oxide (NO) plays a
prominent role in vasodilatation, and inhibition of vascular
smooth muscle cell proliferation, leukocyte adhesion, and
platelet aggregation. L-Arginine serves as the sole source of
nitrogen for NO, whereas asymmetric dimethylarginine (ADMA),
which is an L-arginine derivative, competitively inhibits the reserved.
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methyltransferase methylates arginine residues on proteins.
ADMA and its stereoisomer symmetric dimethylarginine are
generated from proteolysis of methylated nuclear proteins.
Dimethylarginine dimethylaminohydrolase (DDAH) catalyzes
the metabolism of ADMA to L-citrulline and dimethylamine.
Because ADMA competes with L-arginine for the NOS binding
site, a decrease in L-arginine concentration relative to ADMA may
decrease the ability to produce NO and increase arterial stiffness.
Brachial-ankle pulse wave velocity (baPWV) is a feasible method to
estimate arterial stiffness, and the results of a meta-analysis
suggested that baPWV is able to predict cardiovascular events and
mortality [8].
This study sought to determine the relationship between the
L-arginine/ADMA ratio and baPWV in the patients undergoing
coronary angiography. The different progression of arterial
stiffness is a pivotal problem especially among elderly patients.
Therefore, we also conducted subgroup analyses of the relation
between L-arginine/ADMA ratio and baPWV by dividing the
subjects at the age of 65 years.
Methods
Patients undergoing elective cardiac catheterization and
baPWV and serum amino acid measurements from February
2011 to January 2012 at the National Defense Medical College
(Tokorozawa, Japan) were enrolled in the study. Exclusion criteria
included a low ankle brachial index (ABI) of less than 0.9 in both
lower extremities, atrial ﬁbrillation, and hemodialysis. The blood
pressure and baPWV measurements were obtained using an FORM
PWV/ABI automatic waveform analyzer (Omron Colin, Tokyo,
Japan), equipped with electrocardiography, phonocardiography,
and mechanocardiography functions. baPWV was recorded with
patients in the supine position. Electrocardiogram electrodes were
placed on both wrists. A microphone for detecting heart sounds
was positioned on the left edge of the sternum. Cuffs with
tonometric sensors were wrapped around both upper arms and
ankles. The device measured the time intervals between pulse
wavefronts for the right brachial artery and ankle arteries as
pulse transit time (PTT), and automatically calculated baPWV
using the following formula: baPWV = L/PTT (cm/s) (where L is the
estimated brachial-ankle length). Coronary angiography was
performed with a 4 Fr catheter system. Angiograms were taken
from 4 standard projections for each right and left coronary artery.
Coronary artery disease (CAD) was deﬁned as the presence of
coronary stenosis of >75% in at least 1 coronary vessel in the
angiogram, a past history of myocardial infarction, or percutaneous
or surgical coronary intervention.
Blood samples were drawn through a guiding sheath during
coronary angiography before the administration of heparin,
collected into plain tubes, and refrigerated immediately. Serum
was obtained by centrifugation at 3000 rpm for 10 min at 4 8C.
Derivatives of reactive oxidative metabolites were measured in
serum using a free radical test (D-ROMS, Diacron International,
Grosseto, Italy) within 12 h of blood collection. The D-ROMS test
was used to quantify total hydroperoxide levels by measuring
the ability of transition metals to catalyze the formation of free
radicals. In this test, oxidized N,N-diethyl-para-phenylendiamine
was detected spectrophotometrically at 505 nm [9,10].
Further serum samples were stored at 80 8C until required for
amino acid analysis. Serum amino acids were measured by high-
performance liquid chromatography on a SHIMADZU RF-20A
instrument (SHIMADZU, Kyoto, Japan) with a Symmetry C18
column (3.9 mm  150 mm; 5 mm particle size; Waters, Milford,
MA, USA). The detection method used was based on ﬂuorescent
derivatization with AccQ-FluorTM reagent (Waters) in accordancewith previously described methods with several modiﬁcations
[11,12].
The global arginine bioavailability ratio is an index to account
for the proportion of arginine and its major catabolic products,
deﬁned as L-arginine/(L-ornithine + L-citrulline) [13]. This ratio was
proposed to indicate the capacity to provide L-arginine for NO
production.
Other risk factors of CAD were assessed using the following
deﬁnitions. Hypertension was identiﬁed as blood pressure (BP)
above 140/90 mmHg or receiving medication for the condition.
Diabetes mellitus was diagnosed as fasting blood glucose
>126 mg/dl or use of insulin or oral hypoglycemic agents.
Hyperlipidemia was deﬁned as total cholesterol >220 mg/dl,
low-density lipoprotein cholesterol >140 mg/dl, or receiving
anti-hyperlipidemic medication. Smoking index was deﬁned as
the number of cigarette-years smoked. Estimated glomerular
ﬁltration rate (eGFR) was calculated using the Modiﬁcation of
Diet in Renal Disease equation modiﬁed for a Japanese
population [14]. Ejection fraction was measured by echocardi-
ography using Teichholz method or biplane modiﬁed Simpson
method if appropriate.
Statistics
Summary data are presented as mean  standard deviation
(SD) with a 95% conﬁdential interval (CI) for scales of normal
distribution, or as median (interquartile ranges) for non-parametric
variables. The comparison of variables in two groups was performed
with Student’s t-test or Mann–Whitney U-test. Cross-table analyses
were performed using the Chi-squared test or Fisher’s exact test if
appropriate. Univariate and multivariate regression analyses were
performed to identify independent variables from clinical features
and laboratory parameters to explain baPWV. In the multivariate
analysis, all the independent factors correlating with baPWV
(p < 0.1) in the univariate analysis were included in a crude model
(model 1). Next, a stepwise method was used to select effective
explanatory variables from all of the variables used in model 1.
Unnecessary variables were removed to obtain a good-ﬁtting model
(model 2). In model 2, L-arginine was not included for multi-
collinearity. All statistical analyses were performed using JMP
version 10.0 (SAS Institute Inc., Cary, NC, USA). In all analyses,
p < 0.05 was considered statistically signiﬁcant.
Results
Patient characteristics and examinations
Nine patients with ABI <0.9 were excluded, leaving data from
74 patients for analysis. Of these patients, 54 (49 men, 5 women;
mean age, 68  8 years) had CAD and 20 (13 men, 7 women; mean
age, 64  13 years) did not have CAD. Among the patients with CAD,
21 had a history of percutaneous coronary intervention, three had a
history of coronary bypass surgery, and 11 patients had prior
myocardial infarction (Table 1). The numbers of patients with de novo
or residual stenosis (0-, 1-, 2-, 3-vessels) at coronary angiography
were 13, 13, 8, 12 in the subgroup of elderly patients (age  65 years,
n = 46), whereas those were 11, 11, 4, 2 in the younger patients
(age < 65 years, n = 28), respectively (p = 0.194). Thus, the prevalence
of multi-vessel disease tended to be higher in the elderly group in this
study (20/46 vs. 6/28 patients, p = 0.054).
Table 2 shows serum concentrations of amino acids and
traditional coronary risk factors. Regarding physiological measure-
ments, average baPWV was 1756  358 cm/s, with systolic BP of
131  19 mmHg and diastolic BP of 77  11 mmHg. Heart rate (HR)
was 68  13 bpm. Ejection fraction measured by echocardiography
was 66  12%.
Table 1
Patient characteristics.
Total (n = 74) Age  65 (n = 46) Age < 65 (n = 28) p value
Age (years) 67  10 73  5 57  7 <0.001
Sex (male/female) 62 (84%)/12 (16%) 40 (87%)/6 (13%) 22 (79%)/12 (21%) 0.343
BMI (kg/m2) 24  4 23  3 26  4 0.012
Hypertension 57 (77%) 35 (76%) 22 (79%) 0.805
Hyperlipidemia 49 (66%) 28 (61%) 21 (75%) 0.213
Diabetes mellitus 26 (35%) 14 (30%) 12 (43%) 0.278
Current smoking 33 (45%) 19 (41%) 14 (50%) 0.465
Previous conditions
CAD 54 (73%) 36 (78%) 18 (64%) 0.189
OMI 11 (15%) 7 (15%) 4 (14%) 0.913
CABG 3 (4%) 3 (7%) 0 0.285
PCI 21 (28%) 14 (30%) 7 (25%) 0.615
Medications
Beta-blocker 26 (35%) 16 (35%) 10 (36%) 0.935
ACE inhibitor 5 (7%) 5 (11%) 0 0.150
ARB 39 (53%) 25 (54%) 14 (50%) 0.716
Calcium channel blocker 32 (43%) 21 (46%) 11 (39%) 0.592
Furosemide 8 (11%) 8 (17%) 0 0.019
Spironolactone 2 (3%) 1 (2%) 1 (4%) 1.000
Statin 42 (57%) 26 (57%) 16 (57%) 0.958
Insulin 5 (7%) 1 (2%) 4 (14%) 0.065
Aspirin 49 (66%) 32 (70%) 17 (61%) 0.435
Warfarin 7 (10%) 4 (9%) 3 (11%) 0.774
Clopidogrel sulfate 19 (26%) 10 (22%) 9 (32%) 0.320
Signiﬁcant p-values are reported in bold.
BMI, body mass index; CAD, coronary artery disease; OMI, old myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; ACE,
angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
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measurements
Table 3 shows the results of regression analyses. The L-arginine/
ADMA ratio and the serum level of L-arginine were associatedTable 2
Laboratory measurements.
Total (n = 74) A
L-Arginine (mmol/l) 50  10 49
L-Ornithine (mmol/l) 37  15 35
L-Citrulline (mmol/l) 81  27 80
L-Homocysteine (mmol/l) 2.3 (2.0, 3.0) 
L-Cysteine (mmol/l) 79  20 81
ADMA (mmol/l) 0.60  0.21 
SDMA (mmol/l) 0.65  0.24 
L-Arginine/ADMA 91  33 91
GABR 0.45  0.14 
D-ROMS (U CARR) 330  84 343
LDL cholesterol (mg/dl) 105  29 103
TG (mg/dl) 154  94 137
HDL cholesterol (mg/dl) 50  14 50
HbA1C (mg/dl) 5.9  1.1 
Hb (g/dl) 13  1.5 1
Ht (%) 40  4.1 3
Uremic acid (mg/dl) 6.1  1.5 
BUN (mg/dl) 17  5.4 1
Cr (mg/dl) 0.83 (0.74, 1.02) 
eGFR (ml/min) 68  19 61
CRP (mg/dl) 0.30 (0.30, 0.30) 
BNP (pg/ml) 37.8 (16.3, 105) 
Smoking index 768 (275, 1000) 
EF (%) 66  12 65
baPWV (cm/s) 1756  358 1880 
Systolic BP (mmHg) 131  19 130
Diastolic BP (mmHg) 77  11 76
HR (bpm) 68  13 68
Signiﬁcant p-values are reported in bold.
ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; GABR, glo
HDL, high-density lipoprotein; Hb, hemoglobin; Ht, hematocrit; BUN, blood urea nitr
protein; BNP, brain natriuretic peptide; D-ROMS, derivatives of reactive oxidative me
pulse wave velocity; BP, blood pressure; HR, heart rate; bpm, beats per minute.with baPWV (L-arginine/ADMA ratio: b = 0.323, p = 0.005;
Fig. 1A) (L-arginine: b = 0.247, p = 0.034; Fig. 1B). However,
ADMA was not directly related to baPWV. Other factors that
correlated with baPWV were age, history of hypertension, blood
hemoglobin concentration, hematocrit, brain natriuretic peptidege  65 (n = 46) Age < 65 (n = 28) p value
  10 51  10 0.552
  14 39  16 0.229
  24 82  31 0.789
2.3 (2.0, 3.2) 2.3 (1.9, 2.7) 0.308
  18 75  23 0.221
0.58  0.19 0.64  0.24 0.314
0.68  0.22 0.60  0.27 0.208
  33 91  35 0.960
0.45  0.15 0.45  0.13 0.982
  91 307  66 0.071
  27 108  31 0.459
  69 181  120 0.051
  12 51  18 0.729
5.7  0.7 6.2  1.4 0.103
3  1.4 14  1.5 0.002
9  3.8 42  4.1 0.003
6.3  1.5 5.7  1.6 0.162
9  5.5 16  4.7 0.015
0.83 (0.74, 1.02) 0.83 (0.74, 1.02) 0.002
  15 79  21 <0.001
0.30 (0.30, 0.43) 0.30 (0.30, 0.30) 0.418
49.9 (19.5, 128) 26.1 (12.4, 80.9) 0.070
768 (111, 1000) 770 (310, 873) 0.845
  10 66  15 0.902
 345 1554  280 <0.001
  20 134  17 0.399
  10 79  12 0.236
  13 67  13 0.743
bal arginine bioavailability ratio; LDL, low-density lipoprotein; TG, triglyceride;
ogen; Cr, creatinine; eGFR, estimated glomerular ﬁltration rate; CRP, C-reactive
tabolites; HbA1C, hemoglobin A1C; EF, ejection fraction; baPWV, brachial-ankle
Table 3
Regression analysis for prediction of brachial-ankle pulse wave velocity in all patients (n = 74). Adjusted R2 of the model was 0.605 (model 1), and 0.625 (model 2).
Total (n = 74) Univariate Multivariate
Model 1 Model 2
b p b p b p
Age (years) 0.486 <0.001 0.403 <0.001 0.411 <0.001
Sex (male = 1, female = 0) 0.142 0.229
BMI (kg/m2) 0.057 0.633
Hypertension (yes = 1, no = 0) 0.309 0.007 0.133 0.170
Hyperlipidemia (yes = 1, no = 0) 0.109 0.354
Diabetes mellitus (yes = 1, no = 0) 0.151 0.200
Current smoking (yes = 1, no = 0) 0.113 0.339
No. of coronary arteries with stenosis (0, 1, 2, 3) 0.249 0.033 0.072 0.391
Past history of OMI (yes = 1, no = 0) 0.071 0.548
Statin (yes = 1, no = 0) 0.165 0.160
ADMA (mmol/l) 0.156 0.183
SDMA (mmol/l) 0.235 0.044 0.208 0.207
L-Arginine (mmol/l) 0.247 0.034 0.116 0.279
L-Arginine/ADMA 0.323 0.005 0.332 0.008 0.310 <0.001
D-ROMS (U CARR) 0.218 0.062 0.305 0.761
LDL cholesterol (mg/dl) 0.015 0.902
TG (mg/dl) 0.083 0.481
HDL cholesterol (mg/dl) 0.760 0.520
HbA1C (mg/dl) 0.095 0.422
Hb (g/dl) 0.241 0.038 0.193 0.584
Ht (%) 0.280 0.016 0.204 0.553
BUN (mg/dl) 0.295 0.004 0.010 0.926
Cr (mg/dl) 0.322 0.006 0.112 0.619
eGFR (ml/min) 0.401 <0.001 0.151 0.420 0.184 0.042
BNP (pg/ml) 0.335 0.004 0.174 0.039 0.167 0.039
EF (%) 0.012 0.921
Systolic BP (mmHg) 0.303 0.008 0.278 0.034 0.355 <0.001
Diastolic BP (mmHg) 0.230 0.049 0.012 0.922
HR (bpm) 0.316 0.006 0.278 0.003 0.288 <0.001
Signiﬁcant p-values are reported in bold.
BMI, body mass index; OMI, old myocardial infarction; ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; D-ROMS, derivatives of reactive
oxidative metabolites; LDL, low-density lipoprotein; TG, triglyceride; HDL, high-density lipoprotein; HbA1C, hemoglobin A1C; Hb, hemoglobin; Ht, hematocrit; BUN,
blood urea nitrogen; Cr, creatinine; eGFR, estimated glomerular ﬁltration rate; BNP, brain natriuretic peptide; EF, ejection fraction; BP, blood pressure; HR, heart rate;
bpm, beats per minute.
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indices. D-ROMS test also tended to be associated with baPWV.
From coronary angiography, the number of coronary arteries
with stenosis was also associated with baPWV. Additionally,
systolic BP and HR impacted the value of baPWV. In a stepwise
model (model 2; Table 3), the L-arginine/ADMA ratio (b = 0.310,
p < 0.001) remained as an independent predictive factor of
baPWV.Fig. 1. Relationship of baPWV with L-arginine/ADMA ratio (A) and L-arginine (B). Black dot
L-arginine/ADMA ratio was associated with baPWV in all patients and in the subgroup
brachial-ankle pulse wave velocity.Association between baPWV and the L-arginine/ADMA ratio in elderly
patients
In the subgroup of elderly patients (age  65 years, n = 46)
including 36 (78%) patients with CAD, univariate regression
showed that baPWV was associated with hypertension
(b = 0.320, p = 0.030), serum L-arginine (b = 0.393, p = 0.007),
the L-arginine/ADMA ratio (b = 0.350, p = 0.017), BNP (b = 0.331,s indicate patients aged 65 years and white dots indicate those aged <65 years. The
 of older patients (age  65 years). ADMA, asymmetric dimethylarginine; baPWV,
Table 4
Regression analysis for prediction of brachial-ankle pulse wave velocity in elderly patients (age  65 years, n = 46). Adjusted R2 of the model was 0.446 (model 1), and 0.424
(model 2).
Age  65 (n = 46) Univariate Multivariate
Model 1 Model 2
b p b p b p
Age (years) 0.142 0.347
Sex (male = 1, female = 0) 0.115 0.445
BMI (kg/m2) 0.144 0.339
Hypertension (yes = 1, no = 0) 0.320 0.030 0.154 0.255
Hyperlipidemia (yes = 1, no = 0) 0.980 0.517
Diabetes mellitus (yes = 1, no = 0) 0.213 0.155
Current smoking (yes = 1, no = 0) 0.140 0.353
No. of coronary arteries with stenosis (0, 1, 2, 3) 0.120 0.428
Past history of OMI (yes = 1, no = 0) 0.079 0.604
Statin (yes = 1, no = 0) 0.158 0.294
ADMA (mmol/l) 0.177 0.241
SDMA (mmol/l) 0.073 0.628
L-Arginine (mmol/l) 0.393 0.007 0.250 0.053
L-Arginine/ADMA 0.350 0.017 0.260 0.064 0.359 0.004
D-ROMS (U CARR) 0.162 0.283
LDL cholesterol (mg/dl) 0.012 0.937
TG (mg/dl) 0.057 0.705
HDL cholesterol (mg/dl) 0.059 0.698
HbA1C (mg/dl) 0.118 0.435
Hb (g/dl) 0.207 0.168
Ht (%) 0.262 0.079 0.025 0.844
BUN (mg/dl) 0.221 0.139
Cr (mg/dl) 0.178 0.236
eGFR (ml/min) 0.103 0.494
BNP (pg/ml) 0.331 0.024 0.350 0.008 0.337 0.006
EF (%) 0.033 0.828
Systolic BP (mmHg) 0.374 0.011 0.172 0.378 0.346 0.004
Diastolic BP (mmHg) 0.325 0.027 0.100 0.589
HR (bpm) 0.406 0.005 0.246 0.060 0.268 0.028
Signiﬁcant p-values are reported in bold.
BMI, body mass index; OMI, old myocardial infarction; ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; D-ROMS, derivatives of reactive
oxidative metabolites; LDL, low-density lipoprotein; TG, triglyceride; HDL, high-density lipoprotein; HbA1C, hemoglobin A1C; Hb, hemoglobin; Ht, hematocrit; BUN,
blood urea nitrogen; Cr, creatinine; eGFR, estimated glomerular ﬁltration rate; BNP, brain natriuretic peptide; EF, ejection fraction; BP, blood pressure; HR, heart rate;
bpm, beats per minute.
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p = 0.027), and HR (b = 0.406, p = 0.005) (Table 4). Renal function
indices and hemoconcentration were no longer signiﬁcant pre-
dictors of baPWV. A model of multivariate regression analysis
demonstrated that L-arginine/ADMA ratio (b = 0.359, p = 0.004)
was an independent predictive factor of baPWV with other
factors of BNP (b = 0.337, p = 0.006), systolic BP (b = 0.346,
p = 0.004), and HR (b = 0.268, p = 0.028) (model 2; Table 4).
On the other hand, in the subgroup of younger patients
(age < 65 years, n = 28) including 18 patients with CAD (64%), the
L-arginine/ADMA ratio was negatively correlated with baPWV
(b = 0.398, p = 0.036) in univariate analysis. However, L-arginine
concentration alone was not associated with baPWV. Similarly, in a
stepwise model of multivariate regression analysis, it was
suggested that the predictors of baPWV were L-arginine/ADMA
ratio (b = 0.412, p = 0.006), eGFR (b = 0.458, p = 0.003), systolic
BP (b = 0.336, p = 0.020), and HR (b = 0.372, p = 0.012). Adjusted R2
of the model was 0.528.
Discussion
We observed that L-arginine deﬁciency relative to ADMA was
associated with baPWV after statistical adjustment for clinical
features, BP, and HR. Our ﬁndings suggest that the L-arginine/
ADMA ratio, rather than ADMA per se, is predictive of baPWV.
This ﬁnding was similar in the subgroup of elderly patients
(age  65 years) and younger patients (age < 65 years). In
this study, the number of coronary vessels with signiﬁcant
stenosis was associated with baPWV in univariate analysis, butnot signiﬁcant in multivariate analysis. Previously, it was
reported that baPWV was not always concordant with the
severity of CAD [15], although baPWV was a predicting factor of
cardiovascular events [8]. In some reports, other non-invasive
tests relating to arterial stiffness, such as ﬂow-mediated dilation
[15] and augmentation index (AIx) [16], had good correlation
with the severity of CAD.
The results of previous studies suggested that the L-arginine/
ADMA ratio was related to chronic inﬂammation [17], CAD [18,19],
heart failure [20–31], and septic shock [23,24]. However, to date
there have been few studies discussing the association between
the L-arginine/ADMA ratio and arterial stiffness. A double-blind
randomized trial of short-term L-citrulline supplementation in
healthy middle-aged subjects showed that plasma L-arginine and
the L-arginine/ADMA ratio were increased, whereas baPWV was
decreased, in the L-citrulline-treatment group [25]. In another
study examining the efﬁcacy of anti-tumor necrosis factor-a (TNF-
a) therapy on arterial stiffness, the L-arginine/ADMA ratio was
continuously associated with aortic pulse wave velocity after the
initiation of anti-TNF-a therapy [26]. Additionally, ﬂow-mediated
vasodilatation was closely associated with the L-arginine/ADMA
ratio [27]. Our ﬁndings are consistent with those of previous
studies, suggesting that the L-arginine/ADMA ratio is strongly
associated with endothelial function and aortic stiffness. Aging is
the strongest factor for the progression of aortic stiffness [28].
Thus, we analyzed the relationship between the L-arginine/ADMA
ratio and aortic stiffness above the age of 65 years. We found that
the ratio is directly associated with aortic stiffness in the subgroup
of elderly patients.
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explained previously [29–33]. Basically, L-arginine can be lowered
under conditions of dietary deﬁciency, enhanced catabolism, and
a decreased rate of endogenous L-arginine synthesis [34]. Arginase
is a rate-limiting enzyme in the urea cycle converting L-arginine
to L-ornithine and urea. Increased L-arginine catabolism by
enhanced activity of arginase may be an important cause of
chronic L-arginine deﬁciency and endothelial dysfunction. Argi-
nase expression or activity is upregulated in hypertension,
diabetes, oxidative stress, and inﬂammation in human and animals
models of various vascular diseases [35,36]. Moreover, L-ornithine
is the precursor of polyamines that induce proliferation of
vascular smooth muscle cells. Proline and hydroxyproline,
which are the main precursors of collagens, are also synthesized
from L-ornithine. Thus, an increase in L-arginine ﬂux into the
arginase pathway may increase aortic stiffness via metabolic
mechanisms.
On the other hand, higher ADMA level was associated with
cardiovascular adverse outcomes in longitudinal cohort studies
[37]. The metabolism of ADMA can be inﬂuenced by DDAH activity.
ADMA is known to regulate NOS function, and has previously been
associated with vascular physiological function. The radial or
carotid AIx was found to be related to ADMA in several studies
[38,39]. L-Arginine supplementation failed to have a beneﬁcial
effect in some clinical trials in patients with cardiovascular disease
[40]. However, it was previously suggested that the L-arginine/
ADMA ratio might distinguish between patients for whom
L-arginine supplementation would or would not be beneﬁcial
[40]. Thus, the L-arginine/ADMA ratio is expected to be a useful
marker of arterial stiffness, although further studies are necessary.
Several major limitations of this study should be considered.
First, the number of study subjects was small. In this regard,
laboratory measurements relating to diabetes mellitus and
dyslipidemia were not associated with baPWV in our analysis.
Also it is difﬁcult to determine the effect of metabolic disorders on
arterial stiffness in patients receiving medications with such a
small sample size. The second limitation concerns the measure-
ment of baPWV. It is not advisable to include data from patients
with an ABI of <0.9 or those with atrial ﬁbrillation, because
accurate baPWV measurement is not possible in such patients [41].
In view of this, data from patients with severe arteriosclerosis
obliterans in the lower extremities were excluded from the
analysis. Third, we observed that baPWV measurements were
moderately affected by hemodynamics as reported previously
[42,43]. However, the relationship between the L-arginine/ADMA
ratio and baPWV was still signiﬁcant after adjustment for HR and
BP in our analysis.
In conclusion, our ﬁndings suggest that a low L-arginine/ADMA
ratio is associated with a high baPWV in patients undergoing
coronary angiography. This correlation was unchanged in the
subgroup of elderly patients.
Source of funding
This work was supported in part by a grant (to TA) from the
Ministry of Defense, Japan.
Disclosure
None.
Acknowledgments
We would like to thank Azusa Onodera of the Department of
Internal Medicine, National Defense Medical College, for excellent
technical support during HPLC measurements.References
[1] Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy
of arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:932–43.
[2] Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010;74:2257–62.
[3] Brunner EJ, Shipley MJ, Witte DR, Singh-Manoux A, Britton AR, Tabak AG,
McEniery CM, Wilkinson IB, Kivimaki M. Arterial stiffness, physical function,
and functional limitation: the Whitehall II Study. Hypertension 2011;57:
1003–9.
[4] Yasmin McEniery CM, Wallace S, Dakham Z, Pusalkar P, Maki-Petaja K, Ashby
MJ, Cockcroft JR, Wilkinson IB. Matrix metalloproteinase-9 (MMP-9), MMP-2,
and serum elastase activity are associated with systolic hypertension and
arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372–8.
[5] Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large
artery stiffness: from physiology to pharmacology. Hypertension 2004;44:
112–6.
[6] McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin Newby DE,
Cockcroft JR, Wilkinson IB. Endothelial function is associated with pulse
pressure, pulse wave velocity, and augmentation index in healthy humans.
Hypertension 2006;48:602–8.
[7] Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res 2005;66:
286–94.
[8] Vlachopoulos C, Aznaouridis K, Terentes-Printzios D, Ioakeimidis N, Stefanadis
C. Prediction of cardiovascular events and all-cause mortality with brachial-
ankle elasticity index: a systematic review and meta-analysis. Hypertension
2012;60:556–62.
[9] Cighetti G, Allevi P, Anastasia L, Bortone L, Paroni R. Use of methyl malon-
dialdehyde as an internal standard for malondialdehyde detection: validation
by isotope-dilution gas chromatography–mass spectrometry. Clin Chem
2002;48:2266–9.
[10] Cesarone MR, Belcaro G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L,
Barsotti A, Terranova R, Nicolaides A. A simple test to monitor oxidative stress.
Int Angiol 1999;18:127–30.
[11] Heresztyn T, Worthley MI, Horowitz JD. Determination of L-arginine NG, NG-
dimethyl-L-arginine in plasma by liquid chromatography as AccQ-FluorTM
ﬂuorescent derivatives. J Chromatogr B Analyt Biomed Life Sci 2004;B805:
325–9.
[12] Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine,
asymmetric dimethylarginine, and symmetric dimethylarginine in human
plasma and other biological samples by high-performance liquid chromatog-
raphy. Anal Biochem 2002;303:131–7.
[13] Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL. Diminished global arginine
bioavailability and increased arginine catabolism as metabolic proﬁle of
increased cardiovascular risk. J Am Coll Cardiol 2009;53:2061–7.
[14] Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y,
Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, et al.
Estimation of glomerular ﬁltration rate by the MDRD study equitation modi-
ﬁed for Japanese patients with chronic kidney disease. Clin Exp Nephrol
2007;11:41–50.
[15] Koyoshi R, Miura S, Kumagai N, Shiga Y, Mitsutake R, Saku K. Clinical signiﬁ-
cance of ﬂow-mediated dilation, brachial intima–media thickness and pulse
wave velocity in patients with and without coronary artery disease. Circ J
2012;76:1469–75.
[16] Cho SW, Kim BK, Kim JH, Byun YS, Goh CW, Rhee KJ, Ahn HS, Lee BK, Kim BO.
Non-invasively measured aortic wave reﬂection and pulse pressure ampliﬁ-
cation are related to the severity of coronary artery disease. J Cardiol
2013;62:131–7.
[17] van der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CD, Heine RJ, Teerlink T.
Systemic inﬂammation is linked to low arginine and high ADMA plasma levels
resulting in an unfavorable NOS substrate-to-inhibitor ratio: the Hoorn Study.
Clin Sci 2011;121:71–8.
[18] Kocaman SA, Sahinarslan A, Biberoglu G, Hasanoglu A, Akyel A, Timurkaynak T,
Cengel A. Asymmetric dimethylarginine and coronary collateral vessel devel-
opment. Coron Artery Dis 2008;19:469–74.
[19] Selcuk MT, Selcuk H, Temizhan A, Maden O, Ulupinar H, Baysal E, Ozeke O,
Sasmaz A. Asymmetric dimethylarginine plasma concentrations and L-argi-
nine/asymmetric dimethylarginine ratio in patients with slow coronary ﬂow.
Coron Artery Dis 2007;18:545–51.
[20] Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased
endogenous nitric oxide synthase inhibitor in patients with congestive heart
failure. Life Sci 1998;62:2425–30.
[21] Anderssohn M, Rosenberg M, Schwedhelm E, Zugck C, Lutz M, Lu¨neburg N,
Frey N, Bo¨ger RH. The L-arginine-asymmetric dimethylarginine ratio is an
independent predictor of mortality in dilated cardiomyopathy. J Card Fail
2012;18:904–11.
[22] Seljeﬂot I, Nilsson BB, Westheim AS, Bratseth V, Arnesen H. The L-arginine-
asymmetric dimethylarginine ratio is strongly related to the severity of
chronic heart failure. No effects of exercise training. J Card Fail 2011;17:
135–42.
[23] Visser M, Vermeulen MA, Richir MC, Teerlink T, Houdijk AP, Kostense PJ,
Wisselink W, de Mol BA, van Leeuwen PA, Oudemans-van Straaten HM.
Imbalance of arginine and asymmetric dimethylarginine is associated with
markers of circulatory failure, organ failure and mortality in shock patients. Br
J Nutr 2012;107:1458–65.
[24] Brenner T, Fleming TH, Rosenhagen C, Krauser U, Mieth M, Bruckner T, Martin
E, Nawroth PP, Weigand MA, Bierhaus A, Hofer S. L-Arginine and asymmetric
N. Masaki et al. / Journal of Cardiology 65 (2015) 311–317 317dimethylarginine are early predictors for survival in septic patients with acute
liver failure. Mediators Inﬂamm 2012;2012:210454.
[25] Ochiai M, Hayashi T, Morita M, Ina K, Maeda M, Watanabe F, Morishita K.
Short-term effects of L-citrulline supplementation on arterial stiffness in
middle-aged men. Int J Cardiol 2012;155:257–61.
[26] Angel K, Provan SA, Mowinckel P, Seljeﬂot I, Kvien TK, Atar D. The L-arginine/
asymmetric dimethylarginine ratio is improved by anti-tumor necrosis factor-
a therapy in inﬂammatory arthropathies. Associations with aortic stiffness.
Atherosclerosis 2012;225:160–5.
[27] Lind L, Larsson A, Teerlink T. L-Arginine is related to endothelium-dependent
vasodilation in resistance and conduit arteries in divergent ways – the
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study.
Atherosclerosis 2009;203:544–9.
[28] Heffernan KS, Fahs CA, Ranadive SM, Patvardhan EA. L-Arginine as a nutritional
prophylaxis against vascular endothelial dysfunction with aging. J Cardiovasc
Pharmacol Ther 2010;15:17–23.
[29] Morris Jr SM. Arginine metabolism in vascular biology and disease. Vasc Med
2005;10(Suppl. 1):S83–7.
[30] Dioguardi FS. To give or not to give? Lessons from the arginine paradox. J
Nutrigenet Nutrigenomics 2011;4:90–8.
[31] Haines RJ, Pendleton LC, Eichler DC. Argininosuccinate synthase: at the center
of arginine metabolism. Int J Biochem Mol Biol 2011;2:8–23.
[32] Erez A, Nagamani SC, Lee B. Argininosuccinate lyase deﬁciency-argininosuccinic
aciduria and beyond. Am J Med Genet C Semin Med Genet 2011;157:45–53.
[33] Luiking YC, Ten Have GA, Wolfe RR, Deutz NE. Arginine de novo and nitric
oxide production in disease states. Am J Physiol Endocrinol Metab 2012;303:
E1177–89.
[34] Morris Jr SM. Arginases and arginine deﬁciency syndromes. Curr Opin Clin
Nutr Metab Care 2012;15:64–70.[35] Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric
oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007;34:
906–11.
[36] Munder M. Arginase: an emerging key player in the mammalian immune
system. Br J Pharmacol 2009;158:638–51.
[37] Caplin B, Leiper J. Endogenous nitric oxide synthase inhibitors in the biology of
disease: markers, mediators, and regulators. Arterioscler Thromb Vasc Biol
2012;32:1343–53.
[38] Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer
J, Scalera F, Cooke JP, Fliser D, Bode-Bo¨ger SM. ADMA increases arterial
stiffness and decreases cerebral blood ﬂow in humans. Stroke 2006;37:
2024–9.
[39] Weber T, Maas R, Auer J, Lamm G, Lassnig E, Rammer M, O’Rourke MF, Bo¨ger
RH, Eber B. Arterial wave reﬂections and determinants of endothelial function
a hypothesis based on peripheral mode of action. Am J Hypertens 2007;20:
256–62.
[40] Bo¨ger RH. The pharmacodynamics of L-arginine. J Nutr 2007;137(6 Suppl.
2):1650S–5S.
[41] Yokoyama H, Shoji T, Kimoto E, Shinohara K, Tanaka S, Koyama H, Emoto M,
Nishizawa Y. Pulse wave velocity in lower-limb arteries among diabetic
patients with peripheral arterial disease. J Atheroscler Thromb 2003;10:
253–8.
[42] Izuhara M, Shioji K, Kadota S, Baba O, Takeuchi Y, Uegaito T, Mutsuo S, Matsuda
M. Relationship of cardio-ankle vascular index (CAVI) to carotid and coronary
arteriosclerosis. Circ J 2008;72:1762–7.
[43] Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, Miyashita Y, Saiki A,
Takahashi M, Suzuki K, Takata M. Cardio-ankle vascular index (CAVI) as a novel
indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler
Thromb 2011;18:924–38.
